Africa: HIV Vaccine Research Set to Change Focus in Wake of Mosaico Disappointment
[spotlight] Hopes for the Johnson & Johnson (J&J) Mosaico vaccine - the only HIV vaccine candidate in late-stage (Phase 3) clinical trials - were dashed with manufacturer Janssen Pharmaceuticals' recent announcement that the vaccine lacked efficacy in preventing HIV infection. In the wake of this announcement, top South African HIV clinicians are now setting their sights on different approaches to finding an HIV vaccine. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - January 30, 2023 Category: Infectious Diseases Source Type: news

Why inventing a vaccine for AIDS is tougher than for COVID
The 4-decades long effort to create an AIDS vaccine suffered a blow with news that a vaccine in a late stage trial was discontinued because results showed it to be ineffective. What are the obstacles?(Image credit: Luke Dray/Getty Images) (Source: NPR Health and Science)
Source: NPR Health and Science - January 26, 2023 Category: Consumer Health News Authors: Susan Brink Source Type: news

Highly Anticipated HIV Vaccine Fails in Large Trial Highly Anticipated HIV Vaccine Fails in Large Trial
"It ' s obviously disappointing," Anthony Fauci, MD, told MSNBC, noting that other areas of HIV treatment research are promising."I don ' t think that people should give up on the field of the HIV vaccine."WebMD Health News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 20, 2023 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
LEIDEN, THE NETHERLANDS, (January 18, 2023) – The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, today announced the results of an independent, scheduled data review of the Phase 3 Mosaico study (also known as HPX3002/HVTN706) of Janssen’s investigational HIV vaccine regimen. The study’s independent Data and Safety Monitoring Board (DSMB) determined that the regimen was not effective in preventing HIV infection compared to placebo among study participants. No safety issues with the vaccine regimen were identified.In light of the DSMB’s determination, the Mo...
Source: Johnson and Johnson - January 18, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Data Doesn ’t Support New COVID-19 Booster Shots for Most, Says Vaccine Expert
In a perspective published Jan. 11 in the New England Journal of Medicine, vaccine expert Dr. Paul Offit says it’s time to rethink booster recommendations. In the third year of the pandemic, the population’s immune situation is vastly different from what it was in 2019 when SARS-CoV-2 emerged. Now, most people have been vaccinated against the virus, been infected with it (once or multiple times), or both. And the latest data show that the newest booster shot, which targets the Omicron BA.4/5 strain and original virus variants in a bivalent formulation, isn’t that much more effective in generating virus-fi...
Source: TIME: Health - January 11, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Cancer Survivors Say No to HPV Vax; Costly Prostate Cancer; Acupressure Aids Sleep
(MedPage Today) -- New insight into why many cancer survivors refuse vaccination against human papillomavirus. (Cancer) The cost of treating metastatic prostate cancer rose sharply over the past 15 years, largely because of increased use of newer... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 29, 2022 Category: Hematology Source Type: news

Monkeypox Among Those Unvaccinated vs. Vaccinated With JYNNEOS Monkeypox Among Those Unvaccinated vs. Vaccinated With JYNNEOS
The data in this report provides an early indication of the real-world efficacy of vaccination with JYNNEOS for preventing monkeypox. Is a single dose sufficient?Morbidity & Mortality Weekly Report (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 28, 2022 Category: Infectious Diseases Tags: Public Health & Prevention Journal Article Source Type: news

Africa: 2022 Year in Health - New Ebola and Cholera Outbreaks, MPox Emergency, Covid-19 'Not Over'
[UN News] The UN warned that the COVID-19 pandemic is still a cause for global concern, and outbreaks of cholera, Ebola and Monkeypox (now renamed mpox) led to the mobilization of health and aid workers to contain life-threatening illnesses. The UN warned that the aim of eradicating HIV/AIDS by 2030 was under threat, but a new vaccine raised hopes that malaria can be beaten. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 28, 2022 Category: African Health Source Type: news

Dr. Anthony Fauci Is Stepping Down. Here ’s His Advice For His Successor
After Dr. Anthony Fauci steps down as head of the National Institute of Allergy and Infectious Diseases (NIAID) and chief medical advisor to President Biden on Dec. 31, he’ll leave behind a long and storied career. Ahead of his last day, he spoke to TIME from his office at the National Institutes of Health about what’s next for him—and his advice for whoever fills his shoes. This interview has been edited and condensed for clarity. TIME: You’re leaving your leadership positions in the federal government, but you aren’t retiring. What are you calling the next stage in your career? [time-brightc...
Source: TIME: Health - December 20, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

New COVID-19 Trackers in South Sudan Will Help Manage the Next Disease Outbreak
By Acaga Taban Ismail, Former strategic information manager, IntraHealth InternationalDecember 14, 2022South Sudan has experienced numerous disease outbreaks before and after its independence in 2011, which have ranged from mild to severe. The South Sudan Ministry of Health continues to face several challenges managing and providing timely responses to emerging health threats.An underlying reason for this is the country’s shortage of health workers at the national and subnational levels. This is compounded by an untrained health workforce and a lack of data for informed decision-making. Many health workers don&rsqu...
Source: IntraHealth International - December 14, 2022 Category: International Medicine & Public Health Authors: kseaton Tags: Infectious Diseases COVID-19 Digital Health Global health security Source Type: news

How COVID-19 Immunity Works at This Point in the Pandemic
When SARS-CoV-2 was a brand-new virus, it met little resistance in immune-naïve hosts—that is, us. Vaccines, boosters, and infections have increased our immunity to varying degrees. But how much protection do each of these provide at this point in the pandemic? Here’s what researchers are learning about how the human body reacts to COVID-19 and its vaccines and boosters. Vaccines generate more antibodies than infections When the immune system meets a new intruder like SARS-CoV-2, its first response is to churn out sticky antibody proteins that attach to the virus and block it from binding to and infecting ...
Source: TIME: Health - December 13, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Uganda: HIV/Aids Injectable Treatment Drug
[Independent (Kampala)] Kampala, Uganda -- Researchers of the vaccine programme at Uganda Virus Research Institute (UVRI) will start conducting a study among females below 25 years to assess the efficacy of Lenacapavir, an HIV injectable drug. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 12, 2022 Category: African Health Source Type: news

CDC: Mpox Vaccine Is Effective Regardless of Administration Route CDC: Mpox Vaccine Is Effective Regardless of Administration Route
Since the peak of the outbreak in July, mpox cases in the United States have fallen 95%.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 8, 2022 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Battling the Twin Challenge of HIV and Cervical Cancer
A community health worker spreads the message of screening for cervical cancer along with HIV. Credit: Joyce Chimbi/IPSBy Joyce ChimbiNairobi, Dec 6 2022 (IPS) Damaris Anyango* was recently discharged from Kenyatta National Hospital, battling the twin challenge of cervical cancer and HIV. She is 50 years old and was diagnosed with HIV nearly ten years ago. Despite the heightened risk of developing cervical cancer due to the underlying HIV-positive condition, her first cervical cancer screening was undertaken three years ago. “It has been a big challenge dealing with HIV and cervical cancer. When I was told that my HIV te...
Source: IPS Inter Press Service - Health - December 6, 2022 Category: International Medicine & Public Health Authors: Joyce Chimbi Tags: Africa Editors' Choice Featured Gender Headlines Health TerraViva United Nations Women's Health IPS UN Bureau IPS UN Bureau Report Kenya Source Type: news

HIV Vaccine Trial's Pivotal Leap Toward Making Super Antibodies'HIV Vaccine Trial's Pivotal Leap Toward Making Super Antibodies '
' At the most general level, the trial results show that one can design vaccines that induce antibodies with pre-specified genetic features, and this may herald a new era of precision vaccines. 'WebMD Health News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 6, 2022 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news